Research programme: therapeutic and diagnostic proteins - Trubion/Dyax
Latest Information Update: 29 Jun 2009
At a glance
- Originator Trubion Pharmaceuticals
- Developer Dyax; Trubion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammation
Most Recent Events
- 23 May 2007 Trubion Pharmaceuticals has exercised an option to expand its existing research agreement with Dyax Corp
- 06 Oct 2006 Early research in Cancer in USA (unspecified route)
- 06 Oct 2006 Early research in Inflammation in USA (unspecified route)